The Company's topical and transdermal drug delivery platform is based on the use of molecular skin penetration enhancers - transdermal carriers - to deliver drugs to and through the skin directly to the site of pain. Unlike oral medications, Nuvo's topical products do not rely on bloodstream circulation to reach affected parts of the body; consequently they offer site-specific treatment while limiting systemic exposure to the active drug.  Topical products reduce the potential for negative side effects, adverse events and potential drug-drug interactions.

Research studies conducted on behalf of the Company appear to confirm that using a transdermal carrier to deliver an effective pain relieving dose of diclofenac sodium results in significantly lower levels of diclofenac in the bloodstream, compared with published reports for diclofenac delivered orally.

Since acquiring fqubed in December 2005, the Company has increased its focus on identifying and developing a family of synergistic multiplexed molecular skin penetration enhancers (MMPE^™s). The new molecular skin penetration enhancer systems will expand the Companys opportunities for developing drug products that can be delivered to and through the skin.

The Company is actively conducting research on formulations utilizing these systems to build its drug candidate pipeline in pain and other therapeutic areas and has a number of formulations in research or in early stage pre-clinical development.